Morphological assessment of the retina in uveitis

Michael M. Altaweel1,2, Sapna S. Gangaputra1, Jennifer E. Thorne3,4, James P. Dunn5, Susan G. Elner6, Glenn J. Jaffe7, Rosa Y. Kim8, P. Kumar Rao9, Susan B. Reed1, John H. Kempen10
1Fundus Photograph Reading Center, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, USA
2Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA
3Department of Ophthalmology, The Johns Hopkins University, Baltimore, USA
4Department of Epidemiology, The Johns Hopkins University, Baltimore, USA
5Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA
6Kellogg Eye Center, Ann Arbor, USA
7Duke Eye Center, Durham, USA
8Retina Consultants of Houston, Houston, USA
9Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, USA
10Departments of Ophthalmology and Biostatistics & Epidemiology and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, USA

Tóm tắt

The objective of this study is to describe a system for color photograph evaluation in uveitis and report baseline morphologic findings for the Multicenter Uveitis Steroid Treatment (MUST) Trial. Four-hundred seventy-nine eyes of 255 subjects with intermediate, posterior, and panuveitis had stereoscopic color fundus photographs obtained by certified photographers and evaluated by certified graders using standardized procedures to evaluate morphologic characteristics of uveitis. The posterior pole was evaluated for macular edema, vitreoretinal interface abnormalities, and macular pigment disturbance/atrophy; the optic disk was assessed for edema, pallor, or glaucomatous changes. The presence of neovascularization, vascular occlusion, vascular sheathing, and tractional retinal changes was determined. A random subset of 77 images was re-graded to determine the percentage agreement with the original grading on a categorical scale. At baseline, 437/479 eyes had images available to grade. Fifty-three eyes were completely ungradable due to media opacity. Common features of intermediate and posterior/panuveitis were epiretinal membrane (134 eyes, 35 %), and chorioretinal lesions (140 eyes, 36 %). Macular edema was seen in 16 %. Optic nerve head and vascular abnormalities were rare. Reproducibility evaluation found exact agreement for the presence of chorioretinal lesions was 78 %, the presence and location of macular edema was 71 %, and the presence of epiretinal membrane was 71 %. Vertical cup-to-disk ratio measurement had intra-class correlation of 0.75. The MUST system for evaluating stereoscopic color fundus photographs describes the morphology of uveitis and its sequelae, in a standardized manner, is highly reproducible, and allows monitoring of treatment effect and safety evaluation regarding these outcomes in clinical trials.

Tài liệu tham khảo

Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA (2010) The Multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 149(4):550–561 Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):786–806 Hubbard LD, Danis RP, Neider MW, Thayer DW, Wabers HD, White JK, Pugliese AJ, Pugliese MF, Age-Related Eye Disease 2 Research Group (2008) Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Invest Ophthalmol Vis Sci 49(8):3269–3282 Klein BE, Moss SE, Magli YL, Klein R, Johnson JC, Roth H (1987) Optic disc cupping as clinically estimated from photographs. Ophthalmology 94(11):1481–1483 Rothova A (2007) Inflammatory cystoid macular edema. Curr Opin Ophthalmol 18(6):487–492 de Smet MD, Okada AA (2010) Cystoid macular edema in uveitis. Dev Ophthalmol 47:136–147 Taylor SR, Lightman SL, Sugar EA, Jaffe GJ, Freeman WR, Altaweel MM, Kozak I, Holbrook JT, Jabs DA, Kempen JH (2012) The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm 20(3):171–181 Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, Lightman SL, Thorne JE, Vitale AT, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology. 2013 May 21 (Epub ahead of print) Kedhar SR, Thorne JE, Wittenberg S, Dunn JP, Jabs DA (2007) Multifocal choroiditis with panuveitis and punctate inner choroidopathy: comparison of clinical characteristics at presentation. Retina 27(9):1174–1179 Dreyer RF, Gass JDM (1984) Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch Ophthalmol 102:1776–1784 Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH (2005) Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol 140(1):45–51 Ryan SJ, Maumenee AE (1980) Birdshot retinochoroidopathy. Am J Ophthalmol 89:31–45 Fiore T, Iaccheri B, Androudi S, Papadaki TG, Anzaar F, Brazitikos P, D’Amico DJ, Foster CS (2009) Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina 29(7):994–1001 Gass JDM (1987) Inflammatory diseases of the retina and choroid. In: Stereoscopic atlas of macular diseases: diagnosis and treatment, 3rd edn. C.V. Mosby Co, St Louis, pp 505–510 Lim WK, Buggage RR, Nussenblatt RB (2005) Serpiginous choroiditis. Surv Ophthalmol 50(3):231–244 Gupta V, Gupta A, Arora S, Bambery P, Dogra MR, Agarwal A (2003) Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology 110(9):1744–1749 Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174 Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516 Singh R, Gupta V, Gupta A (2004) Pattern of uveitis in a referral eye clinic in north India. Indian J Ophthalmol 52(2):121–125 Paroli MP, Spinucci G, Liverani M, Monte R, Pezzi PP (2009) Uveitis in childhood: an Italian clinical and epidemiological study. Ocul Immunol Inflamm 17(4):238–242 de-la-Torre A, López-Castillo CA, Rueda JC, Mantilla RD, Gómez-Marín JE, Anaya JM (2009) Clinical patterns of uveitis in two ophthalmology centres in Bogota. Colombia Clin Experiment Ophthalmol 37(5):458–466 Suhler EB, Lloyd MJ, Choi D, Rosenbaum JT, Austin DF (2008) Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 146(6):890–6.e8 Kazokoglu H, Onal S, Tugal-Tutkun I, Mirza E, Akova Y, Ozyazgan Y, Soylu M, Batioglu F, Apaydin C (2008) Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 15(5):285–293 Williams GJ, Brannan S, Forrester JV, Gavin MP, Paterson-Brown SP, Purdie AT, Virdi M, Olson JA (2007) The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol 91(1):33–36 Chang PY, Giuliari GP, Shaikh M, Thakuria P, Makhoul D, Foster CS (2011) Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond) 25(4):427–435 Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117(3):576–584 Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V (2011) Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 11(1):35–39 Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Deuter C (2011) Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 249(8):1235–1243 Zhai J, Gu J, Yuan J, Chen J (2011) Tacrolimus in the treatment of ocular diseases. BioDrugs 25(2):89–103 Farvardin M, Afarid M, Mehryar M, Hosseini H (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30(9):1530–1535 Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH (2010) Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 149(3):423–32.e1-2 Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Foster CS (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117(2):356–365 Gangaputra S, Newcomb CW, Liesegang TL, Kaçmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116(11):2188–2198 Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 126(9):1191–1201 Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW, Fluocinolone Acetonide Study Group (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117(3):567–75, 575 Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM, Ozurdex HURON Study Group (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129(5):545–553 Domalpally A, Altaweel MM, Kempen JH, Myers D, Davis JL, Foster CS, Latkany P, Srivastava SK, Stawell RJ, Holbrook JT, MUST Trial Research Group (2012) Optical coherence tomography evaluation in the Multicenter Uveitis Steroid Treatment (MUST) trial. Ocul Immunol Inflamm 20(6):443–447